Clinical trial NCT03664206: Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy
Official title: Assessing Motor Neuron Disease Pathophysiology by Two Novel Methods - Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Cortical Excitability
Keywords: Treshold Tracking Transcranial Magnetic Stimulation
Magnetic Resonance Spectroscopy
Inter-rater agreement
Reproducibililty of Results
Case-control Studies
Biomarkers
Intra-rater agreement
Lead sponsor: Aarhus University Hospital
Sponsor class: OTHER
Collaborators: name: Lundbeck Foundation
name: Aage og Johanne Louis-Hansens Fond
name: The A.P Moeller Foundation for Advancement of Medical Science
name: Danish Council for Independent Research
name: Aarhus University Hospital
name: Central Denmark Region
First posted: 2018-09-10
Enrollment: 0
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients will be recruited among patients examined at the Department of Neurophysiology who are referred for diagnostic neurophysiological examinations without any relation to the proposed project and at the Department of Neurology who are being examining for routine controls.

The healthy participants will be recruited by announcement at the homepage www.forsoegsperson.dk/ and by announcement at Aarhus University and Aarhus University Hospital

Brief summary: Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which cases the death of neurons controlling the voluntary muscles. The death of motor neurons leads eventually to muscle weakness and muscle atrophy and as a consequence thereof, ALS patients die in average within three years after symptom onset due to respiratory failure.

No cure for ALS is currently known, and the medical diagnosis and clinical treatment are impeded by the lack of reliable diagnostic tools for objective disease assessment, and by the limited insight in disease pathophysiology since the underlying disease mechanisms still have not been fully elucidated.

An unbalance in the concentrations of GABA and glutamate, the most important inhibitory and excitatory brain metabolites, is suggested to play a role in the disease mechanisms of ALS. By applying Magnetic Resonance Spectroscopy (MRS), a magnetic resonance method which allows for quantification of brain metabolites, GABA and glutamate concentration can be quantified and thus hopefully elucidate their role in ALS disease mechanism.

Threshold Tracking Transcranial Magnetic Stimulation (TT-TMS) studies carried out by a single research group have demonstrated cortical hyperexcitability (a physiology state in which neurons in the cerebral cortex are easier activated) as an early feature in ALS patients. For this reason, TT-TMS was suggested as a biomarker of ALS by the research group. However, to be able to suggest a test as a biomarker, one must show the test is reliable and reproducible.

The objectives of this study are therefore: to explore the pathophysiology of ALS by investigating the interaction between neuronal networks as assessed by TT-TMS and conventional TMS and MRS, and to investigate the reliability and reproducibility of TT-TMS. The aim is to examine the utility of TT-TMS and MRS as diagnostic tools for objective detection of ALS in the early disease stage.

The study will include 60 participants in total, subdivided into two groups: 30 healthy participants and 30 patients with clinical suspicion of motor neuron disease or ALS. Each participant will undergo examination with TMS and MRS, the primary outcomes will be compared between the two groups and the results from the TMS examinations and the MRS-scans will be correlated.


Eligibility criteria: Inclusion Criteria:

Patients with

* possible, probable or definite ALS according to international criteria;
* progressive muscular atrophy;
* clinical suspicion of motor neuron disease or ALS

Healthy participants: no younger than 45 years of age

Exclusion Criteria:

Patients and healthy participants:

* ealier central or peripheral nervous system disease
* pacemaker or other implants
* pregnancy
* use of medications known to affect central nervous system

Primary outcomes:
measure: short interval intracortical inhibition (SICI) measured by threshold tracking TMS
timeFrame: 8 hours
measure: short interval intracortical inihibition (SICI) measured by conventional TMS
timeFrame: 8 hours
measure: Concentration of GABA and glutamate
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Aarhus
country: Denmark
facility: Department of Clinical Neurophysiology, Aarhus University Hospital
Study officials:
affiliation: Department of Clinical Neuropysiology, Aarhus University Hospital
name: Hatice Tankisi, MD, PhD
role: STUDY_CHAIR
References: